BACKGROUND: The aim of this study was to validate the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based cohort and to study the relevance of revision and extension of the FLIPI. PATIENTS AND METHODS: Data of 353 unselected patients, 1993-2002, in the Eindhoven Cancer Registry, were collected. Follow-up was completed up to 1 January 2006. Multiple imputations for missing covariates were used. Validity was assessed by comparing observed to predicted survival of the original model and of a revised model with other prognostic variables. RESULTS: The original FLIPI stratified our cohort into three different risk groups based on stage, Hb, lactate dehydrogenase, nodal involvement and age. The discrimination between risk groups was not as good as in the original cohort. A model including age in three categories (< or =60/61-70/>70 years) and presence of cardiovascular disease (CVD) (yes/no) resulted in a better prognostic index. The 5-year overall survival rates were 79%, 59% and 28% in the low-, intermediate- and high-risk groups for the extended FLIPI compared with 81%, 66% and 47% for the original FLIPI, respectively. CONCLUSIONS: The performance of the FLIPI was validated in a population-based setting, but could significantly be improved by a more refined coding of age and by including the presence of CVD.
BACKGROUND: The aim of this study was to validate the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based cohort and to study the relevance of revision and extension of the FLIPI. PATIENTS AND METHODS: Data of 353 unselected patients, 1993-2002, in the Eindhoven Cancer Registry, were collected. Follow-up was completed up to 1 January 2006. Multiple imputations for missing covariates were used. Validity was assessed by comparing observed to predicted survival of the original model and of a revised model with other prognostic variables. RESULTS: The original FLIPI stratified our cohort into three different risk groups based on stage, Hb, lactate dehydrogenase, nodal involvement and age. The discrimination between risk groups was not as good as in the original cohort. A model including age in three categories (< or =60/61-70/>70 years) and presence of cardiovascular disease (CVD) (yes/no) resulted in a better prognostic index. The 5-year overall survival rates were 79%, 59% and 28% in the low-, intermediate- and high-risk groups for the extended FLIPI compared with 81%, 66% and 47% for the original FLIPI, respectively. CONCLUSIONS: The performance of the FLIPI was validated in a population-based setting, but could significantly be improved by a more refined coding of age and by including the presence of CVD.
Authors: Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen Journal: Haematologica Date: 2013-09-13 Impact factor: 9.941
Authors: Saskia A M van de Schans; Maryska L G Janssen-Heijnen; Marten R Nijziel; Ewout W Steyerberg; Dick Johan van Spronsen Journal: Haematologica Date: 2010-05-21 Impact factor: 9.941
Authors: Chi Hoon Maeng; Sung Woo Ahn; Seong-Yoon Ryu; Sungjun Han; Young Hyeh Ko; Jun Ho Ji; Won Seog Kim; Seok Jin Kim Journal: Korean J Intern Med Date: 2016-02-22 Impact factor: 2.884
Authors: Mariano Provencio; Pilar Sabín; Jose Gomez-Codina; Maria Torrente; Virginia Calvo; Marta Llanos; Josep Gumá; Cristina Quero; Ana Blasco; Miguel Angel Cruz; David Aguiar; Francisco García-Arroyo; Javier Lavernia; Natividad Martinez; Manuel Morales; Alvaro Saez-Cusi; Delvys Rodriguez; Luis de la Cruz; Jose Javier Sanchez; Antonio Rueda Journal: PLoS One Date: 2017-05-11 Impact factor: 3.240
Authors: Chunyang Li; Vikas Patil; Kelli M Rasmussen; Christina Yong; Hsu-Chih Chien; Debbie Morreall; Jeffrey Humpherys; Brian C Sauer; Zachary Burningham; Ahmad S Halwani Journal: Int J Environ Res Public Health Date: 2021-03-07 Impact factor: 3.390
Authors: George Yang; Matthew Mills; Youngchul Kim; Nicholas B Figura; Catherine Doyle; Daniel Oliver; G Daniel Grass; Timothy Robinson; Julio Chavez; Sungjune Kim Journal: Blood Cancer J Date: 2020-01-02 Impact factor: 11.037